Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03777410 |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma |
| terminated |
| — |
| 33 |
| Travera IncINDUSTRY |
| 1 |
| Jul 3, 2024 |
| clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | terminated | Phase 1 | 32 | Cartesian TherapeuticsINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | terminated | Phase 2 | 17 | Emory UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03451825 | Phase I/II Study of Avelumab in Pediatric Cancer Participants | terminated | Phase 1 | 21 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jun 24, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | Abdullah KhanOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia(PAVE) | terminated | Phase 1 | 16 | Medical College of WisconsinOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04336982 | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 22 | CelgeneINDUSTRY | 5 | May 31, 2024 | clinicaltrials |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | terminated | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides(BDI) | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03175978 | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 2 | IGF Oncology, LLCINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | terminated | Phase 1 | 37 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | terminated | N/A | 25 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | terminated | Phase 2 | 3 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | terminated | Phase 1 | 249 | PfizerINDUSTRY | 2 | May 10, 2024 | clinicaltrials |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML(AML-ViVA) | terminated | Phase 2 | 10 | University Hospital RegensburgOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | terminated | Phase 1 | 32 | SynlogicINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05410574 | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | terminated | N/A | 17 | Washington University School of MedicineOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02718300 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | terminated | Phase 2 | 74 | Incyte CorporationINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | terminated | Phase 2 | 5 | University of California, San FranciscoOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 39 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | terminated | Phase 1 | 23 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT00779480 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002) | terminated | Phase 1 | 14 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04846348 | Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis | terminated | Phase 2 | 1 | Joseph ButterfieldOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05524857 | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | terminated | Phase 1 | 2 | Joseph JurcicOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) | terminated | Phase 2 / Phase 3 | 277 | TG Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 9 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia(AML) | terminated | Phase 3 | 9 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT00893516 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | terminated | Phase 2 | 5 | Emergent BioSolutionsINDUSTRY | 0 | Apr 9, 2024 | clinicaltrials |
| NCT02455024 | An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®(OMNI) | terminated | — | 3 | Ariad PharmaceuticalsINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02446145 | A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients(DELTA) | terminated | Phase 2 | 132 | Technische Universität DresdenOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 105 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | terminated | Phase 2 | 5 | Epizyme, Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | terminated | Phase 1 | 3 | Jorge J. Castillo, MDOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | terminated | Phase 1 / Phase 2 | 9 | Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | terminated | N/A | 2 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 3, 2024source: clinicaltrials